Latest tanezumab trial in patients with OA highlights safety concerns

20 April 2019

knee_arthritis_stock_credit_depositphotos

US pharma majors Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) have announced mixed top-line results from a Phase III study evaluating tanezumab 2.5mg and 5mg, with only the high dose achieving a statistically-significant improvement for pain and physical function over non-steroidal anti-inflammatory drugs (NSAIDs).

Moreover, the pain data were alarming, observers noted, reflecting earlier concerns spotlighted by researchers, and sending Lilly’s shares down 2% and Pfizer 1% lower in after-hours trading on Thursday.

The objective of the study was to compare the long-term joint safety and 16-week efficacy of tanezumab relative to) in patients with moderate-to-severe osteoarthritis (OA) of the hip or knee.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK